Mycophenolate Mofetil Teva (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in conditions that involve immune‑mediated tissue injury or autoimmunity.

• Organ transplant rejection: reduces the risk of acute and chronic graft rejection by inhibiting lymphocyte proliferation.
• Lupus nephritis: controls renal inflammation and helps preserve kidney function in systemic lupus erythematosus.
• Other autoimmune disorders: provides immunosuppression for diseases where T‑ and B‑cell activity drives pathology.

• Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blocks de novo guanosine nucleotide synthesis, a pathway essential for proliferation of activated T and B lymphocytes, thereby dampening the adaptive immune response.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea and vomiting: gastrointestinal discomfort that may improve with food.
• Diarrhea: frequent loose stools, sometimes requiring fluid replacement.
• Headache: mild to moderate intensity.
• Tremor: fine shaking of the hands or limbs.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Infections: increased susceptibility to bacterial, viral or fungal infections.
• Bone marrow suppression: leukopenia, anemia or thrombocytopenia.
• Malignancy: heightened risk of lymphoproliferative disorders.
• Severe liver injury: elevated transaminases or hepatitis.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.

• Monitor blood counts: perform complete blood count to detect leukopenia or anemia.
• Assess renal function: check serum creatinine and eGFR, especially in transplant recipients.
• Avoid use in pregnancy: potential teratogenic effects require contraception for women of child‑bearing potential.
• Evaluate infection risk: screen for latent infections and vaccinate before treatment when possible.
• Adjust dose in hepatic impairment: consider reduced exposure in patients with liver dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Live vaccines: may cause uncontrolled infection due to immunosuppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate exposure.
• Antacids containing aluminum or magnesium: decrease absorption when taken simultaneously.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: combined use may increase risk of hyperkalemia and renal dysfunction.
• Warfarin: may alter INR, requiring more frequent coagulation monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate nephrotoxicity, especially in patients with compromised kidney function.